Table 1. Selected SERD Properties.

				agonist/antagonist profile
molecular type	DC50 MCF-7	Dmax MCF-7	IC50 (antiproliferation) MCF-7	breast	uterus (% of control w. wt)	bone	references
Steroidal
ICI 164,383		>95%	39 nM	antagonist	40–50%	antagonist	(3c, 5a, 22a)
ICI 182,780	0.4 nM	>95%	0.6 nM	antagonist	42%	antagonist	(5a, 5b, 12a, 12c)
Acrylic Acids
GW5638/GW7604	390 nM/1.7 nM	82%/86%	985 nM/5 nM	antagonist	weak antagonist	agonist	(12a)
GDC-0810	0.7 nM	87%	2.5 nM	antagonist	weak antagonist	agonist	(12a)
AZD9496	0.14 nM	>95%	0.04 nM	antagonist	weak agonist	unknown	(12b, 12c)
Basic Side Chain
RAD1901	1.5 nM	∼70%	8.9 nM	antagonist/agonist	weak agonist	unknown	(15b, 22b)
bazedoxifene	10 nM	∼70%	0.24 nM	antagonist	weak agonist	agonist	(15c, 16)
GDC-0927	0.3 nM	97%	0.2 nM	antagonist	∼60%	unknown	(22c, 22d)
GDC-9545	0.04 nM	84%	0.26 nM	antagonist	∼50%	unknown	(23a)
AZD9833	0.16 nM	99%	5.0 nM	antagonist	not reported	unknown	(19b)
PROTACs
ARV-471	0.9 nM	>95%	not reported	antagonist	∼45%	unknown	(23b)
ERD-308	0.17 nM	>99%	0.77 nM	antagonist	not reported	unknown	(23c)